Additional Ring Containing Patents (Class 514/317)
  • Patent number: 11278651
    Abstract: The present disclosure relates to a hemodialysis membrane for the treatment of restless leg syndrome (RLS), especially in severe and very severe cases and/or in patients which suffer from kidney failure and already receive hemodialysis. The present disclosure therefore also relates to methods of treating restless leg syndrome. The treatment and method encompasses using a hemodialysis membrane which is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 8.5 and 14.0 kD and a MWCO of between 55 kD and 130 kD.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: March 22, 2022
    Assignee: Gambro Lundia AB
    Inventors: Angelito A. Bernardo, Angela Sofia Rivera Florez, Lars-Goran Nilsson, Rafael Mauricio Sanabria Arenas, Alfonso Bunch Barrera
  • Patent number: 11254641
    Abstract: A preparation method according to the present invention makes it possible to industrially produce large amounts of highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield by use of commercially available reagents and solvents. In addition, the use of novel intermediates according to the present invention makes it possible to produce highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: February 22, 2022
    Assignee: HK inno.N Corporation
    Inventors: Jae Hong Kweon, Eun Sun Kim, Hyuk Woo Lee, Dong Hyun Ko, Chae Young Ryu, Kwang Do Choi, SeungPyeong Heo
  • Patent number: 11234973
    Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: February 1, 2022
    Assignees: PRILENIA NEUROTHERAPEUTICS LTD., NATIONAL UNIVERSITY OF SINGAPORE, Agency for Science, Technology and Research
    Inventors: Michael Hayden, Mahmoud Abdulhossein Pouladi
  • Patent number: 11213518
    Abstract: Ligands of the mu, kappa, and delta opioid receptors and methods of using them are disclosed. In particular, the invention relates to the discovery of new opioid receptor ligands based on molecular dynamics simulations of conformational states of the ? opioid receptor and the use of the identified opioid receptor ligands as analgesics, anti-diarrheal agents, and overdose reversal agents.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: January 4, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Memorial Sloan-Kettering Cancer Center
    Inventors: Evan N. Feinberg, Vijay S. Pande, Susruta Majumdar, Gavril Pasternak
  • Patent number: 11209426
    Abstract: Methods and compositions for detecting and diagnosing Parkinson's disease are disclosed.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: December 28, 2021
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Howard E. Gendelman, R. Lee Mosley, Jessica A. Saunders
  • Patent number: 11167012
    Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: November 9, 2021
    Assignees: The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
  • Patent number: 11135211
    Abstract: A method for treating a impulse control disorder in a patient comprising administering to the patient an effective amount of pimavanserin or a pharmaceutical acceptable salt thereof.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 5, 2021
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventor: Ethan S. Burstein
  • Patent number: 11099162
    Abstract: In an LC system using an ODS column (15) and UV detector (17), a cannabis-derived sample is analyzed by gradient elution using a phosphoric acid aqueous solution and phosphoric-acid-containing methanol. A control unit (3) regulates the openings of solenoid valves in a mixer (12) so that the increase rate of the mixture ratio of the phosphoric-acid-containing methanol in a second part of the analysis period is higher than in a first part. By this operation, ten active ingredients (including Total THC, Total CBD and CBN) contained in cannabis can be satisfactorily separated within an analysis time which is equal to or even shorter than approximately 30 minutes. Each ingredient separated by the column (15) is detected by the UV detector (17). An active ingredient identification processor (22) identifies the ten active ingredients based on the retention times of the peaks on a chromatogram created from the detection signals.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: August 24, 2021
    Assignee: SHIMADZU CORPORATION
    Inventor: Yohei Arao
  • Patent number: 11000519
    Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: May 11, 2021
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal Geva, Aric Orbach, Michael Hayden
  • Patent number: 10946006
    Abstract: The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: March 16, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Robert S. Chao, Miroslav Rapta
  • Patent number: 10934303
    Abstract: The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERR?) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical composition containing same as an active ingredient.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: March 2, 2021
    Assignees: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL, KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Sung Yeoun Hwang, Sung Jin Cho, Jina Kim, Jungwook Chin, Hayoung Hwang, In-Kyu Lee, Yong-Hyun Jeon, Jaetae Lee, Jae-Han Jeon, Sang Wook Kim
  • Patent number: 10921318
    Abstract: The present invention relates to the use of a control marker for implementing analysis methods on spots, in particular in the context of multiplex analyses. The present invention thus relates to solid supports containing said control marker, their preparation method and their use in analysis methods. The present invention makes it possible to verify the presence, location and/or integrity of the spots at the end of the analysis method, and thus to secure the obtained results while guaranteeing that the yielded result indeed results from a present, intact and localized spot.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: February 16, 2021
    Assignee: BIO-RAD EUROPE GMBH
    Inventors: Agnes Roseline Claude Pouzet, Vincent Doury, Laurent Emmanuel Fournier, Christophe Rene Roger Vedrine
  • Patent number: 10864192
    Abstract: Compositions and methods for mitigating a pathology following brain trauma or at least a portion of a cascade of a pathology associated therewith, including compositions and methods for treating concussion or preventing the onset of anecrotic cell death in neurons. Exemplary compositions for treating concussion include an active compound comprising one or more of: phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof; and one or more pharmaceutically acceptable excipients. The one or more excipients can be combined with the active compound to form an extended, controlled-release medicament that delivers a therapeutic concentration of the active compound over a period of time.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: December 15, 2020
    Assignee: Aristea Translational Medicine Corporation
    Inventor: Robert E. Becker
  • Patent number: 10787422
    Abstract: The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, R3, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLA2 inhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLA2 enzyme.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: September 29, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Jianhua Shen, Yiping Wang, Xinde Chen, Wenwei Xu, Kai Wang
  • Patent number: 10751328
    Abstract: Methods for treating or relieving at least one symptom of urticarial disorders including chronic idiopathic urticaria, angioedema, and anaphylaxis, or a combination of these disorders in a mammal, including humans. The method comprises administering to the mammal a therapeutically effective amount of pramipexole, dexpramipexole or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: August 25, 2020
    Inventors: Oral Alpan, Benjamin I. Enav
  • Patent number: 10702512
    Abstract: The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS), fibromyalgia (FM) and depression, as well as of combinations thereof. Related treatment methods, pharmaceutical compositions and combination kits are also disclosed.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: July 7, 2020
    Assignee: A. CARLSSON RESEARCH AB
    Inventors: Arvid Carlsson, Carl-Gerhard Gottfries
  • Patent number: 10617639
    Abstract: Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 14, 2020
    Assignee: Signpath Pharma, Inc.
    Inventor: Lawrence Helson
  • Patent number: 10576073
    Abstract: The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: March 3, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Robert S. Chao, Miroslav Rapta
  • Patent number: 10548901
    Abstract: A method of treating or preventing a respiratory disease in a pig is described that includes administering to the pig in need thereof an effective amount of meloxicam or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: February 4, 2020
    Inventors: Ingo Lang, Ioannis Papatsas
  • Patent number: 10543201
    Abstract: Methods are provided for treating conditions including chronic pelvic pain, in which there are palpable trigger points of local areas of muscle restriction and spasticity that recreate or refer pain of patients complaints upon palpation, chronic pelvic pain syndrome, pelvic floor myalgia, pelvic floor dysfunction, interstitial cystitis, levator ani syndrome, coccygodynia, prostatodynia, piriformis syndrome, anal sphincter pain, bowel movement pain, post bowel movement pain, ejaculatory pain, post ejaculatory pain, sitting pain, post bowel movement pain, rectal pain, tailbone pain, urinary frequency, urinary urgency, urinary hesitancy, post urinary pain, overactive bladder, perineal pain, penile pain, vaginismus, anismus, sexual dysfunction, reduced level of ejaculate or reduced penile erection, myofascial pain in muscle tissue of a patient who has one or more trigger points in the muscle tissue, or the pain/sensitivity of pelvic floor muscle trigger points and specific areas of myofascial restriction detected
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: January 28, 2020
    Inventor: David Wise
  • Patent number: 10459055
    Abstract: The present disclosure provides systems and methods for magnetic resonance fingerprinting (MRF). The method including steps comprising acquiring a plurality of MRF signals from a plurality of excitation volumes within a subject, wherein at least two of the plurality of excitation volumes differ in location within the subject, and wherein each of the excitation volumes partially overlap to form an overlap volume. The method also includes comparing the plurality of MRF signals acquired from the overlap volume with a dictionary of signal evolutions, determining one or more physical parameters of the overlap volume within the subject, and generating a report at least indicating the one or more physical parameters of the overlap volume within the subject.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 29, 2019
    Assignee: Case Western Reserve University
    Inventors: Mark A. Griswold, Yun Jiang
  • Patent number: 10441579
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: October 15, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • Patent number: 10357458
    Abstract: Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: July 23, 2019
    Assignee: Signpath Pharma Inc.
    Inventor: Lawrence Helson
  • Patent number: 10238642
    Abstract: The invention relates to methods for treating neurogenic orthostatic hypotension and symptoms thereof using 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: March 26, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventor: Sharathchandra S. Hegde
  • Patent number: 10226454
    Abstract: The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: March 12, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Lori Jean Patterson, Robert S. Chao, Miroslav Rapta
  • Patent number: 10214514
    Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: February 26, 2019
    Assignees: Curis, Inc., Genentech, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Patent number: 10183025
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 22, 2019
    Assignee: Novartis AG
    Inventors: David Beattie, Urs Baettig, Darren Mark Le Grand, Andrew Stuart Lister, Jeffrey McKenna, David William Pearce, David Andrew Sandham, Oliver Ross Steward, Christopher Thomson
  • Patent number: 10111860
    Abstract: Compositions and methods for mitigating a pathology following brain trauma or at least a portion of a cascade of a pathology associated therewith, including compositions and methods for treating concussion or preventing the onset of anecrotic cell death in neurons. Exemplary compositions for treating concussion include an active compound comprising one or more of: phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof; and one or more pharmaceutically acceptable excipients. The one or more excipients can be combined with the active compound to form an extended, controlled-release medicament that delivers a therapeutic concentration of the active compound over a period of time.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 30, 2018
    Inventor: Robert E. Becker
  • Patent number: 10047049
    Abstract: This invention provides a pridopidine base in a solid form, a method of preparing the solid pridopidine base, and a composition comprising the pridopidine base including a pharmaceutical composition.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: August 14, 2018
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Offir Barel, Ramy Lidor-Hadas, Ronen Gottesfeld, Orel Yosef Mizrahi, Anders Olof Ingemar Bergh, Ba-Vu Nguyen
  • Patent number: 10029997
    Abstract: The invention describes compounds that inhibit both HDAC and GSK3? (i.e., HDAC/GSK3? dual inhibitors). The invention further describes compositions containing these HDAC/GSK3? dual inhibitors, as well as methods and kits using these HDAC/GSK3? dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3? to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3?. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: July 24, 2018
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Mouad Edderkaoui, Ramachandran Murali, Stephen Pandol
  • Patent number: 9988375
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: June 5, 2018
    Assignee: CORTEXYME, INC.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Patent number: 9944644
    Abstract: The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 17, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
  • Patent number: 9855225
    Abstract: The present invention includes methods and compositions for treating a transplant recipient by administration of a CB2 receptor agonist either alone or in combination with one or more active pharmaceutical ingredients to block the rejection of foreign tissue and prolong grafted organs, tissues and cells.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: January 2, 2018
    Assignee: TEMPLE UNIVERSITY OFFICE OF TECHNOLOGY TRANSFER
    Inventors: Toby K. Eisenstein, Rebecca R. Hartzell, Martin W. Alder, Joseph J. Meissier
  • Patent number: 9809540
    Abstract: A compound which is the hydrobromide salt of N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N?-(3-fluoro-2-methylphenyl)urea, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: November 7, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Francis Dominic Sanderson, Sarah Mary Vallance
  • Patent number: 9708299
    Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: July 18, 2017
    Assignees: Genentech, Inc., Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Patent number: 9708253
    Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: July 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, T. G. Murali Dhar, Bin Jiang, Ananta Karmakar, Arun Kumar Gupta, Zhonghui Lu, Carolyn A. Weigelt
  • Patent number: 9675603
    Abstract: Provided are pharmaceutical compositions in solid form comprising a selective modulator of PPAR-? suitable for oral dosage to treat subjects having PPAR-? mediated conditions. Provided further are methods of manufacturing the compositions, and methods of treating a PPAR-? mediated condition.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: June 13, 2017
    Assignee: InteKrin Therapeutics, Inc.
    Inventors: Kathleen M. Lee, Linda Higgins, Dennis Lanfear
  • Patent number: 9675599
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: June 13, 2017
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland
  • Patent number: 9662308
    Abstract: The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: May 30, 2017
    Assignee: Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG
    Inventors: Bernd Clement, Joscha Kotthaus, Jürke Kotthaus, Dennis Schade
  • Patent number: 9603844
    Abstract: The present invention provides methods of inhibiting abnormal growth of cells, with the methods comprising contacting the cells with at least one of the sensitizing compounds disclosed herein in an amount sufficient to inhibit cell growth. The present invention also provides methods of treating and/or reducing the likelihood of being diagnosed with breast cancer, with the methods comprising administering to a subject in need of treatment thereof at least one of the sensitizing compounds disclosed herein.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: March 28, 2017
    Assignee: Georgetown University
    Inventors: Eliot M Rosen, York A Tomita
  • Patent number: 9580811
    Abstract: The present invention aims to provide a method for producing a dispersion of metal nanoparticles which enables to control the shape and the particle diameter over a wide range, a dispersion of metal nanoparticles having superior dispersion stability, and a method for producing the same. In addition, the present invention further aims to provide a dispersion of metal nanoparticles which has a volume resistivity of 2×10?6 to 6×10?6 ?·cm and is suitable for use as an electrically conductive material, and a method for producing the same. Moreover, the present invention further aims to provide a method for synthesizing metal nanoparticles which can produce metal nanoparticles suitable for use as electrically conductive materials by synthesizing the metal nanoparticles from a insoluble metal salt which is free of corrosive materials.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: February 28, 2017
    Assignee: Mitsubishi Materials Corporation
    Inventors: Kazuhiko Yamasaki, Airi Katagiri, Masahide Arai, Yoshiaki Takata, Toshiharu Hayashi
  • Patent number: 9580810
    Abstract: The present invention aims to provide a method for producing a dispersion of metal nanoparticles which enables to control the shape and the particle diameter over a wide range, a dispersion of metal nanoparticles having superior dispersion stability, and a method for producing the same. In addition, the present invention further aims to provide a dispersion of metal nanoparticles which has a volume resistivity of 2×10?6 to 6×10?6 ?·cm and is suitable for use as an electrically conductive material, and a method for producing the same. Moreover, the present invention further aims to provide a method for synthesizing metal nanoparticles which can produce metal nanoparticles suitable for use as electrically conductive materials by synthesizing the metal nanoparticles from a insoluble metal salt which is free of corrosive materials.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: February 28, 2017
    Assignee: Mitsubishi Materials Corporation
    Inventors: Kazuhiko Yamasaki, Airi Katagiri, Masahide Arai, Yoshiaki Takata, Toshiharu Hayashi
  • Patent number: 9511070
    Abstract: Methods, uses, medicaments, and unit doses for treating viral diseases are described herein. The methods, uses, medicaments, and unit doses include (a) substituted piperidine and piperazine carboxamides, or a pharmaceutically acceptable salt thereof and (b) one or more pharmaceutically acceptable carriers, excipients or diluents, or combinations thereof. Viral diseases include hepatitis C virus, HIV, BVDV, and Coronavirus infections.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: December 6, 2016
    Assignee: NovaDrug, LLC
    Inventor: Eliezer Huberman
  • Patent number: 9446029
    Abstract: Methods for managing visceral pain in mammalian subjects are described, in which a NK-1 receptor antagonist is administered to the subject before, during or after administration of general anesthesia. The methods and uses of NK-1 receptor antagonists described herein provide improved visceral pain management and MAC reduction when used with volatile anesthetics for general anesthesia.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: September 20, 2016
    Assignee: Colorado State University Research Foundation
    Inventors: Pedro Boscan, David Twedt
  • Patent number: 9427479
    Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: August 30, 2016
    Assignee: MedImmune LLC
    Inventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
  • Patent number: 9409893
    Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: August 9, 2016
    Assignee: Jacobus Pharmaceutical Company, Inc.
    Inventors: Gavin David Heffernan, David Penman Jacobus, Kurt William Saionz, Guy Alan Schiehser, Hong-Ming Shieh, Wenyi Zhao
  • Patent number: 9375421
    Abstract: A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 28, 2016
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 9303249
    Abstract: The present application provides for compositions comprising high concentrations of acid ?-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: April 5, 2016
    Assignee: AMICUS THERAPEUTICS, INC.
    Inventors: Kenneth Valenzano, John Crowley, Richie Khanna, John Flanagan
  • Patent number: 9212180
    Abstract: The present invention relates generally to compounds that inhibit the binding of menin and MLL or MLL fusion proteins and methods of use thereof. In particular embodiments, the present invention provides compositions comprising piperidine-containing compounds and methods of use thereof to inhibit the interaction of menin with MLL oncoproteins (e.g., MLL1, MLL2, MLL-fusion oncoproteins), for example, for the treatment of leukemia, solid cancers, diabetes, and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, MLL-PTD and/or menin.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: December 15, 2015
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, VANDERBILT UNIVERSITY
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Sunil Kumar Upadhyay, Shaun R. Stauffer, Rocco D. Gogliotti, Timothy J. Senter
  • Patent number: 9162982
    Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: October 20, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Lori Jean Patterson, Eric L. Stangeland, Sheila Zipfel, Daniel D. Long